Reported Earnings • May 31
First quarter 2026 earnings released: kr0.02 loss per share (vs kr0.016 loss in 1Q 2025) First quarter 2026 results: kr0.02 loss per share (further deteriorated from kr0.016 loss in 1Q 2025). Revenue: kr443.0k (up 216% from 1Q 2025). Net loss: kr11.8m (loss widened 13% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Board Change • May 21
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Independent Director Lars Hedbys was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Tillkännagivande • Apr 23
Xintela AB (publ), Annual General Meeting, May 22, 2026 Xintela AB (publ), Annual General Meeting, May 22, 2026, at 09:00 W. Europe Standard Time. Location: medicon village (building 601), scheeletorget 1, in lund., lund Sweden Tillkännagivande • May 15
Xintela AB (publ), Annual General Meeting, Jun 13, 2025 Xintela AB (publ), Annual General Meeting, Jun 13, 2025, at 09:00 W. Europe Standard Time. Location: at medicon village building 601, scheeletorget 1, lund Sweden Tillkännagivande • Apr 15
Xintela AB (publ) Decreases Patient Number in XSTEM Clinical Study in Difficult-To-Heal Leg Ulcers Xintela AB (publ) has amended the study protocol in the clinical phase I/IIa study with XSTEM on patients with difficult-to-heal venous leg ulcers to complete the study earlier. The number of patients to be enrolled in the study has been reduced from 12 to 6. The primary goal of the study, to investigate safety and tolerability, will be achieved even with the reduced number of patients. XSTEM, which consists of allogeneic (donated) integrin a10b1-selected mesenchymal stem cells, is developed and manufactured by Xintela. The Phase I/IIa clinical study in patients with difficult-to- heal venous leg ulcers is a placebo-controlled, randomized study. Patients receive one dose of XSTEM or placebo applied to the wound and are assessed weekly for 10 weeks and after 4 months. The primary goal of the studies is to show safety and tolerability and, also to investigate the preliminary effect of XSTEM in wound healing. The number of patients to been enrolled in the study has been reduce from 12 to 6 due to slow recruitment. To date 5 patients have been dosed of which 4 have completed the study. The amended clinical study protocol has received regulatory approval. Tillkännagivande • Mar 18
Xintela AB (publ) Announces Stem Cell Product XSTEM Shows Safety and Positive Efficacy Results in Knee Osteoarthritis Clinical Study Xintela announced interim analysis of data from the knee osteoarthritis clinical study shows safety and positive efficacy results, 18 months after treatment with XSTEM. The results demonstrate statistically significant and clinically meaningful improvements in knee pain and knee function. In addition, the results of XSTEM treatment show an improvement in bone structure and also a trend of stopping cartilage breakdown, supporting a disease-modifying potential of XSTEM in the treatment of osteoarthritis. The highest dose of the three dose levels tested showed the best therapeutic effect. XSTEM, which consists of allogeneic (donated) integrin a10b1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela is conducting a first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, where three dose levels (4, 8 and 16 million stem cells) of the stem cell product XSTEM are being evaluated (8 patients/dose level). A total of 24 patients (41-75 years) with symptomatic moderate knee osteoarthritis (KL grade II-III) have received one injection of XSTEM into the knee joint. The primary goal of the study is to assess safety and tolerability of XSTEM. In addition, preliminary efficacy signals, such as reduced pain and improved joint function, as well as reduced degeneration of cartilage and other joint tissues, are being investigated every six months. An interim analysis of study data up to 18 months after treatment with X STEM, has now been performed. In summary, the results showed safety and sustained efficacy on pain, knee function and cartilage and bone structure. The major findings are described below: The study will be completed after the 24-month follow-up of the highest dose level of XSTEM and the final results are planned to be reported in September 2025. Patients at the lowest and mid dose levels have completed the study, 18 months after dosing. Tillkännagivande • Feb 20
Xintela Appoints Lucienne Vonk as Chief Scientific Officer Xintela announces that Lucienne Vonk, previously Director Musculoskeletal Diseases at Xintela, has been appointed Chief Scientific Officer. She takes over the role from the CEO Evy Lundgren-Åkerlund. Lucienne Vonk has a strong background in cell-based therapies for cartilage regeneration, both in academic and industry settings. She obtained her PhD at the Academic Center for Dentistry Amsterdam (The Netherlands) investigating cartilage tissue engineering, after which she joined the department of Orthopaedics at the University Medical Center Utrecht (The Netherlands). There, her research focused on biological and cell-based therapies for cartilage regeneration, and she was part of a team that developed a one-stage cell-based treatment for focal articular cartilage defects. She also headed the Scientific Liaison department at CO.DON AG (Germany). She has held several positions on standing committees of the International Cartilage Regeneration and Joint Preservation Society (ICRS) and is senior associate editor for the Journal of Cartilage & Joint Preservation. Tillkännagivande • Dec 21
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study Xintela AB (publ) announced that the results from Xintela's preclinical EQSTEM study in horses with post-traumatic osteoarthritis (OA) have been published in the scientific journal Cartilage. The results demonstrate less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. Xintela has previously published that integrin a10b1-selected stem cells from horses, EQSTEM, which are the equivalent of the human stem cell product XSTEM®?, reduce cartilage and bone damage in a post-traumatic OA model in horses (Delco et al., Am J Sports Med. 2020;48:612). The study results that now have been published in the scientific Journal, further support a disease modifying effect of EQ STEM by Cartilage showing significantly less cartilage damage in treated horses compared to untreated horses. In addition, EQSTEM significantly reduced lameness in treated horses which indicates less pain and improved function of the treated joint. The results also demonstrated that specific biological factors were increased in the joint after injection of EQSTEM which provide further understanding of the mechanisms of action of EQSTEM. The study was conducted in collaboration with the University of Copenhagen. New Risk • Nov 24
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 77% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr69m free cash flow). Share price has been highly volatile over the past 3 months (44% average weekly change). Negative equity (-kr29m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€11.8m market cap, or US$12.9m). Tillkännagivande • Oct 15
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study Xintela's first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing three different dose levels of the stem cellproduct XSTEM®. The Safety Review Committee for the clinical study has now assessed all three dose levels safe at the planned three-month follow-up. XSTEM,which consists of allogeneic (donated) integrin 101-selected mesenchymal stem cells, is being developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) have received one injection of XSTEM into the knee joint. Three different dose levels have so far been dosed in 24 patients (8 patients/dose level). The study enables an expansion of up to a total of 54 patients. Each patient is followed for 18 months with an efficacy reading every six months. The primary goal of the study is to show that XSTEM is safe. In addition, preliminary efficacy signals, such as reduced pain and improved joint function as well as reduced breakdown of joint cartilage and regeneration of damaged cartilage are being investigated. Tillkännagivande • Jun 23
Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study Xintela completed XSTEM dosing at third and final dose level in knee osteoarthritis clinical study. All patients on the third and final dose level have now been dosed in Xintela's first- in-human study (Phase I/IIa) for the treatment of knee osteoarthritis in Australia where three different dose levels of the stem cell product XSTEM® are being tested. The primary goal of the study is to show that XSTEM is safe but also to investigate preliminary efficacy signals. XSTEM, which consists of allogeneic (donated) integrin 101-selected mesenchymal stem cells, is developed and produced by Xintela. Patients with moderate knee osteoarthritis (grade II-III) receive one injection of XSTEM into the knee joint. Three different dose levels are being evaluated in a total of 24 patients with the possibility to increase the number up to 54 patients. The first two dose levels have been considered safe at the one month follow-up and all patients have now been dosed at the third and final dose level. Each patient will be followed for 18 months with efficacy readings every six months. The primary goal is to show that XSTEM is safe, but also investigate preliminary efficacy signals, such as reduced pain, reduced degradation of articular cartilage, regeneration of damaged cartilage and improved joint function. Xintela has previously reported that patients treated with the lowest dose of XSTEM, experience reduced pain and improved function of the knee after six months. Tillkännagivande • Jun 02
Xintela AB (publ) Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress Xintela AB (publ) is conducting a first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis in Australia where three different dose levels of the stem cell product XSTEM®? are being tested. The primary goal of the study is to show that XSTEM is safe but also to investigate preliminary efficacy signals. The treatment of 16 patients on the first and second dose levels with XSTEM has been assessed as safe at a one-month follow-up by the Safety Review Committee. The first efficacy results from the lowest dose show that patients experience reduced pain and improved joint function in the knee six months after the injection of XSTEM. XSTEM, which consists of allogeneic (donated) integrin a10b1-selected mesenchymal stem cells, is developed and produced by Xintela. Patients with moderate knee osteoarthritis (grades II-III) receive one injection of XSTEM into the knee joint. Three different dose levels are being evaluated in a total of 24 patients with the possibility to increase the number up to 54 patients. The first two dose levels have been considered safe and 6 out of 8 patients have been dosed at the third and final dose level. Xintela has now started to evaluate the first efficacy results for patients at the lowest dose level and can see an early trend showing that patients experience reduced pain and improve joint function in the knee six years after the injection with XSTEM. Each patient will be followed for 18 months with efficacy readings every six months. The primary goal is to show that X STEM is safe, but also to investigate preliminary efficacy signal, such as reduced pain, reduced degradation of articular cartilage, regeneration of damaged cartilage and improved joint function. Safety data from all dose levels and up to 12 months efficacy data from the lowest dose level are expected in 2023. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Lars Hedbys was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 10
Xintela Starts Next Dose Level of Xstem in Knee Osteoarthritis Clinical Study Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. The Safety Review Committee for the clinical study assessed the treatment of the eight patients on the lowest XSTEM dose level at the one-month follow-up, concluded the dose is safe, and approved the continuation to dosing of patients at the second dose level. XSTEM, which consists of allogeneic (donated) integrin a10ß1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) receive one injection of XSTEM into the knee joint. Three different dose levels are being evaluated in up to 54 patients and each patient will be followed for 18 months with an efficacy reading every 6 months. The primary goal is to show that XSTEM is safe, and also to investigate preliminary efficacy signals, such as reduced breakdown of joint cartilage, regeneration of damaged cartilage, and improved joint function. Safety data from all dose levels and early efficacy results are expected in 2023. Tillkännagivande • Oct 01
Xintela Completes Dosing of Xstem First Dose Level in Knee Osteoarthritis Clinical Study Xintela's first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. All patients at the lowest dose level have now been dosed. XSTEM, which consists of allogeneic (donated) integrin 101-selected mesenchymal stem cells, is developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) receive an injection of XSTEM into the knee joint. Three different dose levels are being evaluated in up to 54 patients and each patient will be followed for 18 months with an efficacy reading every 6 months. The primary goal is to show that XSTEM is safe, and also to investigate preliminary efficacy signals, such as reduced breakdown of joint cartilage, regeneration of damaged cartilage, and improved joint function. Initial safety data are expected before the end of this yearand early efficacy results in 2023. Tillkännagivande • Sep 23
Xintela AB (Publ) Appoints Peter Ekolind as Acting CEO, Effective October 1, 2022 Targinta's board has appointed Peter Ekolind as acting CEO, starting from October 1, 2022, as a part-time assignment, due to Per Norlén's resignation as CEO. Peter Ekolind has more than 30 years of experience from operational and strategic positions at management level in the pharmaceutical and medical technology industry, from multinational companies to small development companies. Previous experiences include various positions such as CEO, business area manager and COO. Peter has good knowledge in product development, sales, marketing, capitalization, preclinical development and GMP manufacturing. For the past two years, Peter has worked as COO in Xintela. Tillkännagivande • Sep 21
Xintela AB (publ) Starts Clinical Study with XSTEM for Difficult-To-Heal Leg Ulcers Xintela AB (publ) started its second clinical study (Phase I/IIa) with XSTEM® for the treatment of difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin 101-selected mesenchymal stem cells, is developed and manufactured by Xintela. The recruitment of patients for the Phase I/IIa study for the treatment of difficult-to-heal venous leg ulcers, which is carried out at Linköping University Hospital, has now begun.Twelve patients with difficult-to-heal venous leg ulcers will receive a treatment of XSTEM or placebo applied to the wound and will then be followed up weekly for 10 weeks and after 6 months. The primary goal of the study is to show that the treatment is safe but also that XSTEM has a positive effect on wound healing. Early safety and efficacy data are expected before the end of 2022. Tillkännagivande • Jul 06
Xintela Receives Approval for Clinical Study with XSTEM on Difficult-to-Heal Venous Leg Ulcers Xintela AB (publ) has received approval from the Medical Products Agency for a clinical Phase I/IIa study with XSTEM in patients with difficult-to-heal venous leg ulcers. XSTEM consists of integrin a10ß1-selected and quality-assured mesenchymal stem cells and is produced in Xintela's own GMP facility. In the clinical study, which will be carried out in collaboration with Professor Folke Sjöberg and his team at the University Hospital in Linköping, 12 patients with difficult-to-heal venous leg ulcers will be treated with XSTEM or placebo. XSTEM/placebo will be applied onto the wounds and the patients will be followed for 10 weeks to evaluate safety and wound healing effect. The study will start after the summer and early results are expected by the end of 2022. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Lars Hedbys was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 06
Xintela Starts Clinical Study of XSTEM® in Knee Osteoarthritis Xintela started its first-in-human study (Phase I/IIa) with XSTEM® for the treatment of knee osteoarthritis in Australia. XSTEM, which consists of allogeneic (donated) integrin alpha10beta1- selected mesenchymal stem cells, is developed and manufactured by Xintela. Patients with moderate knee osteoarthritis (grade II-III) will receive a single injection of XSTEM into the knee joint. Three different doses will be assessed in up to 54 patients and each patient will be followed for 18 months. The primary goal is to show that XSTEM is safe, but also to look for preliminary efficacy signals, such as reduced cartilage degradation, regeneration of damaged cartilage and improved joint function. Initial safety data is expected before the end of 2022 and early efficacy data during 2023. Tillkännagivande • Jan 19
Xintela AB (Publ) Receives Grant of 4.8 Million SEK from Vinnova Xintela AB (Publ) has been granted SEK 4.8 million from Vinnova within the call New and improved biological drugs in healthcare. The grant will support a clinical phase I/IIa study to evaluate Xintelas stem cell product XSTEM for the treatment of patients with difficult-to-heal leg ulcers. The project, which will be partly financed by Vinnova, aims to evaluate the safety and efficacy of Xintelas stem cell product XSTEM in a clinical phase I/IIa study for treatment of difficult-to-heal venous leg ulcers, a painful disease that affects about 4% of the population over 65 years. The clinical study will be performed in collaboration with Professor Folke Sjöberg and his team at the Burn Center at Linköping University Hospital. Xintelas application received the maximum grant, where 9 applications were granted a total of SEK 45 million in funding. Tillkännagivande • Aug 12
Xintela Signs Agreement with CRO for Phase I/II study Xintela continues to take important steps towards its first clinical trial with the drug candidate XSTEM-OA. This spring, the company was granted permission to produce cell therapy products in its own GMP facility and has now signed an agreement with the Australian CRO GreenLight Clinical to conduct the first clinical trial in humans with the candidate. Recent Insider Transactions • Jun 27
CFO & Finance Director recently bought €5.0k worth of stock On the 21st of June, Gunnar Telhammar bought around 20k shares on-market at roughly €0.25 per share. This was the largest purchase by an insider in the last 3 months. This was Gunnar's only on-market trade for the last 12 months. Tillkännagivande • May 22
Xintela AB (Publ) Receives Permission from the Medical Products Agency to Produce Cell Therapy Products Xintela AB (publ) announced that the company has received permission from the Medical Products Agency to produce cell therapy products, so-called advanced therapy drugs (ATMPs), in its own GMP facility. Tillkännagivande • Mar 14
Xintela AB (publ) Publishes Results from Glioblastoma Antibody Study Xintela announced that the results of the company’s preclinical glioblastoma study with function-blocking antibodies have been published in the renowned international scientific journal Cancers. The publication shows, among other things, that antibodies directed to the company’s target molecule integrin 101 significantly reduce the growth of the aggressive and deadly brain tumor glioblastoma in an animal model. Glioblastoma is the most common and most aggressive brain tumor form in adults and there is an enormous need for new and better treatment strategies. The published article demonstrates that function-blocking antibodies directed against the target molecule integrin 101 significantly reduce the tumor volume of glioblastoma tumors in an animal model and that the antibodies inhibit glioblastoma cell growth, survival and migration (movement). The work has been carried out in collaboration with IVRS (In Vivo Research Services) in Lund. The results show that Xintela’s targeting antibodies are a promising new strategy for the treatment of glioblastoma. Xintela has approved patents that protect integrin 101 antibodies for the treatment of CNS tumors including glioblastoma. Is New 90 Day High Low • Mar 06
New 90-day low: €0.26 The company is down 16% from its price of €0.31 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. Reported Earnings • Feb 27
Full year 2020 earnings released: kr0.68 loss per share (vs kr1.10 loss in FY 2019) Full year 2020 results: Net loss: kr50.3m (loss widened 16% from FY 2019). Tillkännagivande • Jan 09
Xintela AB (publ) Receives Notice of Allowance from USPTO for the Treatment of Brain Tumors Xintela AB (publ) announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's patent application covering targeted antibody treatment of tumors of the central nervous system (CNS). Xintelas patent application 15/550,837 in the USA protects the use of the target molecule integrin 101 for antibody based treatment of tumors of the CNS, including glioblastoma. Xintela has now received a Notice of Allowance which means that the USPTO intends to grant the patent after completion of certain formal steps. Once granted, the patent can be kept in force until 2036. The corresponding European patent application was recently granted by the European Patent Office (EPO). Xintela has previously reported that the company's ADC (Antibody-Drug Conjugate) antibodies have the capability to kill glioblastoma cells, both in cell based studies and in an animal model. The results have been published in the journal Cancers (2019, Vol. 11, p. 587). Additionally, in December 2019, Xintela announced that the company's function-blocking antibodies have demonstrated an inhibitory effect on glioblastoma tumor growth in a preclinical study. Tillkännagivande • Dec 17
Xintela Recruits Jeffrey Abbey to Targinta as Senior Management Advisor Xintela AB (publ) announced that Jeffrey Abbey has been recruited as a Senior Management Advisor to support further development of the wholly owned subsidiary Targinta. Mr. Abbey has more than 20 years of experience in the biopharmaceutical industry and has spent much of his career focused on the development of innovative oncology therapies. Previously, Mr. Abbey was chief executive officer of Argos Therapeutics, an immuno-oncology company which he led from early-stage development through completion of a phase 3 trial, raised over
$250 million in equity financing, including an initial public offering on US Nasdaq, and built to an organization of 140 people. Tillkännagivande • Nov 28
Xintela AB (publ) to Report Fiscal Year 2020 Results on Feb 26, 2021 Xintela AB (publ) announced that they will report fiscal year 2020 results on Feb 26, 2021 Tillkännagivande • Nov 13
Xintela AB (Publ) Appoints Lars Hedbys to Its Board of Directors Xintela AB (publ) announced that Lars Hedbys has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Lars at the next shareholders meeting. In the meantime, Lars will be adjoined to future Board meetings. Lars Hedbys has significant experience from leading positions and Board roles in the pharmaceutical, biotech and medtech industries with several senior positions in AstraZeneca, including Site General Manager, AstraZeneca R&D, Lund. He currently has several Board assignments including Chairman of the Board of Scandinavian ChemoTech AB (listed) and IAmPatient AB, and member of the Boards of RhoVac AB (listed), Cell Invent AB and Vetiqure AB. Among previous assignments are CEO of Idogen AB (listed), acting CEO of Pharmiva AB and Chairman of the Board of Lund Life Science Incubator AB. Is New 90 Day High Low • Nov 06
New 90-day low: €0.28 The company is down 39% from its price of €0.46 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period. Tillkännagivande • Oct 27
Xintela Announces Promising Results of Human Stem Cells XSTEM in Preclinical Acute Respiratory Distress Syndrome Study Xintela announced that the company's selected human stem cells XSTEM show a therapeutic effect in ARDS (Acute Respiratory Distress Syndrome) in an ongoing preclinical study in pigs. ARDS is a life-threatening lung complication that may affect severely ill covid-19 patients. Xintela previously announced that XSTEM-ARDS is being evaluated in a well established preclinical pig model of ARDS and that Vinnova awarded a grant of SEK 1 million to fund the study. The preclinical study is being performed in collaboration with Professor Sandra Lindstedt and her team at the Cardio-thoracic surgery clinic, Skåne University Hospital in Lund and Lund University. The study involves twelve animals with the lung complication ARDS. Six animals receive intravenous treatment with XSTEM-ARDS and six control animals receive an injection without cells. During the study, various clinical parameters are monitored to measure lung and circulatory function and the health status of the animals. Blood and tissue samples are also collected and will be analyzed when the study is completed. Two animals remain to be treated before the final results can be compiled. The results so far show that XSTEM-ARDS had a positive therapeutic effect in all four animals that received stem cells. This positive effect is based on, among other things, improvement in the lungs' ability to oxygenate blood and stabilization of the blood circulatory system, compared to no improvement in the control animals, who remained in the life-threatening ARDS condition throughout the study. Is New 90 Day High Low • Oct 16
New 90-day low: €0.35 The company is down 26% from its price of €0.48 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period. Tillkännagivande • Sep 03
Xintela AB (publ) to Report Nine Months, 2020 Results on Nov 27, 2020 Xintela AB (publ) announced that they will report nine months, 2020 results on Nov 27, 2020 Tillkännagivande • Jul 17
Xintela AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 36.70987 million. Xintela AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 36.70987 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 15,295,779
Price\Range: SEK 2.4
Transaction Features: Rights Offering 
